Want to see JP:7774 full AI Analyst Report?
Top Page
Japan Tissue Engineering Co., Ltd.
(7774)
Select Model
Select Model
Rating:46Neutral
Price Target:
¥804.00
▲(39.83% Upside)
Action:Reiterated
Date:09/10/26
The score is held down primarily by deteriorating financial performance (widening losses and rising cash burn), partially mitigated by a strong, low-debt balance sheet. Technicals are mixed—near-term weakness but stronger longer-term trend—while valuation is unfavorable due to negative earnings and no dividend yield data.
Positive Factors
Low Leverage
An effectively debt-free balance sheet materially reduces solvency and refinancing pressure, preserving financial flexibility while the company develops and commercializes regenerative therapies. This structure provides greater capacity to absorb operating volatility over the next several quarters.
Negative Factors
Revenue Decline
Revenue has not sustained its strong 2024 increase, instead declining in each of the following two years. Continued top-line contraction could weaken operating leverage, limit investment capacity, and make a durable recovery in profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
An effectively debt-free balance sheet materially reduces solvency and refinancing pressure, preserving financial flexibility while the company develops and commercializes regenerative therapies. This structure provides greater capacity to absorb operating volatility over the next several quarters.
Read all positive factors
Japan Tissue Engineering Co., Ltd. (7774) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥34.44B
Dividend YieldN/A
Average Volume (3M)111.59K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth3.43%
EPS Growth-53.59%
CountryJP
Employees200
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.84
Shares Outstanding40,610,200
10 Day Avg. Volume115,470
30 Day Avg. Volume111,586
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.75
Price to Sales (P/S)11.09
P/FCF Ratio-43.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.9
Revenue Forecast (FY)¥5.05B
Japan Tissue Engineering Co., Ltd. Business Overview & Revenue Model
Company Description
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Deve...
How the Company Makes Money
The company primarily makes money by commercializing regenerative medicine products and associated services. Its core revenue stream is product sales to healthcare providers (typically via Japan’s healthcare reimbursement framework) of approved, t...
Japan Tissue Engineering Co., Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
74
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.52B | 2.18B | 2.46B | 2.51B | 2.03B | 2.10B |
| Gross Profit | 1.56B | 1.23B | 1.47B | 1.67B | 1.12B | 1.24B |
| EBITDA | -94.39M | -392.06M | -124.74M | 242.31M | -596.67M | -373.21M |
| Net Income | -440.13M | -734.75M | -255.30M | 143.17M | -729.32M | -497.89M |
Balance Sheet | ||||||
| Total Assets | 5.91B | 5.68B | 6.51B | 6.99B | 6.88B | 7.60B |
| Cash, Cash Equivalents and Short-Term Investments | 3.35B | 3.25B | 3.89B | 4.27B | 4.13B | 4.93B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 133.00K | 936.00K |
| Total Liabilities | 766.06M | 592.71M | 687.95M | 908.43M | 946.15M | 931.66M |
| Stockholders Equity | 5.14B | 5.09B | 5.83B | 6.08B | 5.94B | 6.67B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -562.67M | -224.48M | 78.23M | -771.66M | -327.82M |
| Operating Cash Flow | 0.00 | -488.02M | -148.37M | 274.14M | -622.60M | -225.25M |
| Investing Cash Flow | 0.00 | 253.03M | -232.53M | -242.23M | 1.12B | -116.48M |
| Financing Cash Flow | 0.00 | 0.00 | -3.00K | -134.00K | -803.00K | -823.00K |
Japan Tissue Engineering Co., Ltd. Technical Analysis
Positive
575.00
Price Trends
773.42
Positive
688.72
Positive
635.48
Positive
Market Momentum
8.86
Positive
54.94
Neutral
41.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7774, the sentiment is Positive. The current price of 575 is below the 20-day moving average (MA) of 850.65, below the 50-day MA of 773.42, and below the 200-day MA of 635.48, indicating a neutral trend. The MACD of 8.86 indicates Positive momentum. The RSI at 54.94 is Neutral, neither overbought nor oversold. The STOCH value of 41.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7774.
Japan Tissue Engineering Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | ¥41.21B | 60.89 | ― | ― | -47.32% | ― | |
46 Neutral | ¥34.44B | -78.87 | ― | ― | 3.43% | -53.59% | |
44 Neutral | ¥14.34B | -30.28 | ― | ― | -18.71% | -246.54% | |
44 Neutral | ¥9.04B | -7.84 | ― | ― | -56.16% | 3.12% | |
43 Neutral | ¥74.00B | -20.00 | -37.79% | ― | ― | 5.71% |
* General Sector Average
JP:7774
Japan Tissue Engineering Co., Ltd.
848.00
333.00
64.66%
JP:4592
SanBio Co
948.00
-1,593.00
-62.69%
JP:4593
Healios KK
304.00
-269.00
-46.95%
JP:4978
ReproCELL Inc.
138.00
-62.00
-31.00%
JP:7776
CellSeed Inc.
229.00
-245.00
-51.69%
Japan Tissue Engineering Co., Ltd. Corporate Events
Japan Tissue Engineering Revises FY2026 Financial Disclosure, Lifts Product Business Profit Figure
Jul 31, 2026
Japan Tissue Engineering Co., Ltd. has issued a correction to its FY2027 Q1 financial results briefing materials originally disclosed on July 30, 2026, and has posted the revised version on its website. The changes clarify that multiple fiscal-yea...
Japan Tissue Engineering Turns Profitable as JACC Orders Surge in Regenerative Medicine Push
Jul 30, 2026
Japan Tissue Engineering reported strong FY2027 first-quarter results, with net sales reaching 766 million yen and a sharp improvement in operating and net profits, supported by growing demand for its JACC therapy in osteoarthritis. The company ac...
Japan Tissue Engineering Turns Profitable and Projects Strong FY2027 Growth
Jul 30, 2026
Japan Tissue Engineering Co., Ltd. reported a sharp rebound in earnings for the three months ended June 30, 2026, with net sales rising 79.9% year on year to ¥766 million and net income turning positive at ¥52 million, versus a loss in t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.